What is Amondys 45 (casimersen) and what do people mean by “annual cost”?
Amondys 45 is an antisense drug used for Duchenne muscular dystrophy (DMD) patients with a confirmed mutation amenable to skipping exon 45. The phrase “annual cost” typically refers to the drug’s list price charged per year based on the labeled dosing and typical treatment duration.
How much does Amondys 45 cost per year?
Public, widely reported pricing for Amondys 45 has been in the range of roughly $300,000+ per year at list price, depending on the patient’s weight and dose frequency used in practice. Actual out-of-pocket cost can be much lower with insurance coverage, patient assistance, or other negotiated pricing.
Why can the annual cost vary from patient to patient?
The total yearly spend depends on several factors:
- Patient weight and the prescribed dose, since casimersen dosing is weight-based.
- Dose frequency and the time span used to calculate “annual” treatment.
- Negotiated pricing, rebates, and whether the payer covers the full list price.
What affects your actual price (what you pay) versus the “annual cost” figure?
Even if the headline annual list price is very high, your out-of-pocket cost depends on:
- Insurance type and benefit design (copay/coinsurance/coverage limits).
- Prior authorization and coverage criteria for exon-45 skipping.
- Whether manufacturer assistance programs or third-party support apply.
Are there cheaper alternatives if cost is a concern?
For exon-specific DMD therapies, costs can differ by product and by insurance coverage. Coverage decisions and eligibility are usually driven by the patient’s exact mutation and prescriber criteria, so the relevant comparison is typically between treatments matched to the patient’s mutation rather than a single “cheapest DMD drug.”
If you want, I can estimate a more precise annual cost for a specific scenario
If you tell me the patient’s weight (or approximate weight range), your country, and whether you want list price or expected out-of-pocket, I can help narrow down what “annual cost” would mean for that situation.
Sources
I don’t have enough provided information here to cite a specific annual cost figure reliably. If you share the pricing source you’re looking at (or the country/benefit context), I can translate it into an annual estimate and cite it accurately.